Francois Guilhot

Poitiers, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients.

Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients.

Journal: Cancer immunology, immunotherapy : CII

Published: September 11, 2025

Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia.

Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia.

Journal: Blood

Published: September 11, 2024

The need to set up a national register of adult cancers in France

The need to set up a national register of adult cancers in France

Journal: Bulletin du cancer

Published: February 25, 2024

Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).

Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).

Journal: British journal of haematology

Published: May 13, 2022

The EHA Research Roadmap: Malignant Myeloid Diseases.

The EHA Research Roadmap: Malignant Myeloid Diseases.

Journal: HemaSphere

Published: May 17, 2021

Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.

Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.

Journal: British journal of haematology

Published: February 14, 2021

Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.

Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.

Journal: Cancer

Published: September 08, 2020

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.

Journal: Leukemia

Published: May 15, 2020

Human cells for therapeutics purpose: State of the art

Human cells for therapeutics purpose: State of the art

Journal: Bulletin de l'Academie nationale de medecine

Published: February 27, 2020

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Journal: Leukemia

Published: February 10, 2020

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.

Journal: Leukemia

Published: January 24, 2020

Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.

Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.

Journal: Cancer

Published: January 13, 2020

Showing 1-12 of 92

Last Updated: 09/26/2026